865757-06-8Relevant academic research and scientific papers
Novel hypoxia-targeting Pt(iv) prodrugs
Xu, Zichen,Zhao, Jian,Gou, Shaohua,Xu, Gang
, p. 3749 - 3752 (2017)
Novel Pt(iv) prodrugs targeting hypoxia inducible factor HIF-1α were prepared for evaluating their antitumor activity on hypoxic cancer cells for the first time. The resulting Pt(iv) prodrug exhibited effective inhibition on tumor growth in the HCT-116 xe
A gemcitabine-based conjugate with enhanced antitumor efficacy by suppressing HIF-1α expression under hypoxia
Gou, Shaohua,Liao, Zhixin,Xu, Zichen,Zhang, Bin
, (2021)
Hypoxia is one of the unique features of tumor physiology. Hypoxia inducible factor (HIF-1α), as a major transcription factor in response to hypoxia, has been considered as a promising tumor-specific target for anticancer therapy. The formation of a hypox
Hypoxia-Targeting Organometallic Ru(II)-Arene Complexes with Enhanced Anticancer Activity in Hypoxic Cancer Cells
Zhao, Jian,Li, Wanchun,Gou, Shaohua,Li, Shuang,Lin, Shengqiu,Wei, Qianhui,Xu, Gang
, p. 8396 - 8403 (2018/07/25)
As hypoxia is an important factor to limit chemotherapeutic efficacy in tumors, we herein report three ruthenium(II)-arene complexes containing a hypoxia inducible factor-1α inhibitor (YC-1), which endow the organometallic complexes with potential for hyp
Arene-ruthenium complex as well as preparation method and application thereof
-
Paragraph 0038; 0041; 0042, (2018/09/13)
The invention relates to an arene-ruthenium complex as well as a preparation method and an application thereof. The complex has the structure shown in a formula I in the description, wherein R represents 0-6 substituent groups which are independently sele
Ligand for preparing ruthenium compound with antitumor activity as well as preparation method and application thereof
-
Paragraph 0018; 0025; 0026, (2018/10/19)
The invention relates to a ligand for preparing a ruthenium compound with antitumor activity as well as a preparation method and application thereof. HIF-1alpha inhibitor YC-1 is added into the ruthenium compound, the ruthenium (II) with biological activi
Novel fused pyrazolyl compound
-
Page/Page column 4; 6, (2010/02/14)
A fused pyrazolyl compound of the following formula: wherein A, Ar1, Ar2, R1, R2, R3, and R4, are as defined herein. Also disclosed is a pharmaceutical composition containing an effective a
